India has administered more than 80 lakh (8 million) doses of the Human Papillomavirus vaccine under the National HPV Vaccination Campaign, the Ministry of Health and Family Welfare announced on 11 September 2026. The campaign was launched by the Prime Minister in February 2026 and offers free, voluntary, single-dose vaccination to 14-year-old girls, with parental consent, at government health facilities.
Four States — Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram — have reached 100% coverage of their identified target cohorts. Uttar Pradesh has vaccinated the largest absolute number, more than 22 lakh adolescent girls.
The virus, and why a vaccine can pre-empt a cancer
Human papillomavirus is a family of more than a hundred related viruses, most of which cause nothing worse than warts or a transient infection the immune system clears on its own. A small subset is oncogenic. Two members of that subset, HPV types 16 and 18, are responsible for roughly 70% of cervical cancers. Two others, types 6 and 11, cause most genital warts.
What makes cervical cancer unusual among cancers is that it has a single dominant, identifiable, transmissible cause. Persistent infection with an oncogenic HPV type drives changes in the cells of the cervix that progress — slowly, typically over ten to twenty years — through pre-cancerous stages to invasive cancer. That long latency is both the tragedy and the opportunity. The tragedy is that women present late, when treatment is difficult. The opportunity is that an intervention delivered in adolescence, long before exposure, can interrupt the chain at its first link.
This is the logic of primary prevention, and it is precisely why the target group is 14-year-olds rather than adult women. The vaccine is prophylactic, not therapeutic: it primes the immune system against the virus before infection occurs. It does not treat an existing infection, and it does not treat cancer. Students working through immunity and vaccination should be able to state that distinction cleanly, because the difference between a preventive vaccine and a therapeutic one is a standard conceptual question.
The vaccines in use are virus-like particle vaccines. They present the L1 capsid protein of the virus assembled into an empty shell — the outer form of the virus with none of its genetic material — so the immune system learns to recognise it without any possibility of infection. CERVAVAC, developed by the Serum Institute of India and granted market authorisation by the Drugs Controller General of India in 2022, was India's first indigenously developed HPV vaccine and is quadrivalent, covering types 6, 11, 16 and 18.
Why one dose
The original schedules were two or three doses. The shift to a single dose rests on evidence assessed by the World Health Organization's Strategic Advisory Group of Experts on Immunization in 2022, which concluded that a single dose delivers protection comparable to multi-dose schedules in the target age group.
For a country vaccinating a cohort of this size, the operational consequence is enormous. A single dose means one session per girl rather than a return visit months later — no follow-up tracking, no drop-out between doses, roughly a third to a half of the cold-chain volume and health-worker time, and a far simpler school-and-facility calendar. Programmes lose more coverage to missed second doses than to initial refusal, so removing the second dose removes the biggest leak in the pipe.
The scale of the cohort
Registrar General of India estimates put the annual cohort of 14-year-old girls at approximately 1.2 crore. That figure is the denominator against which every coverage percentage in this campaign should be read, and it is a useful anchor for anyone revising India's population structure and demography: a single-year age cohort of one sex is already larger than the total population of most countries.
| Coverage band | States and Union Territories |
|---|---|
| 100% of identified cohort | Gujarat, Uttar Pradesh, Madhya Pradesh, Mizoram |
| Above 90% | Bihar, Andhra Pradesh, Assam |
| Above 85% | Karnataka |
| Above 60% | Chhattisgarh, Sikkim, Kerala, Telangana, Odisha |
The spread is instructive. High-coverage performers include both a large, densely populated northern State and a small north-eastern one, which cuts against the assumption that population size determines programme performance. The Ministry attributes the results to sustained community mobilisation, coordinated State implementation and district-level health teams working through the existing public-health delivery network, including in rural, remote and geographically difficult areas.
Digital plumbing and the trust problem
Coverage is tracked on U-WIN, the digital platform for routine immunisation that grew out of the architecture built for the COVID-19 vaccination drive. It lets programme managers see coverage at district level, identify gaps and locate missed beneficiaries, which converts a national percentage into an actionable list of names and villages. This is the quiet difference between a campaign that reaches 60% and stalls, and one that grinds through the last mile.
The harder problem is not logistics but confidence. The campaign has deliberately foregrounded credible information and community engagement, working through paediatricians, gynaecologists, experts from institutions such as AIIMS, teachers, and frontline workers including ASHAs and ANMs, specifically to address parental concerns and counter misinformation. Any vaccine offered to adolescent girls attracts rumour, and a single viral message can shut down a district's uptake for a season.
The safety architecture is built to answer that. All sessions are conducted under the supervision of trained Medical Officers at government facilities, and every facility is linked to a 24×7 facility for the management of rare Adverse Events Following Immunization (AEFI) — timely assessment, monitoring and treatment of any event that does occur. Globally, more than 800 million doses of HPV vaccine have been distributed, which is an unusually deep well of real-world safety data to draw on.
Where the world stands
HPV vaccination began as a high-income-country intervention and has spread down the income ladder. At present, 87% of upper-middle-income countries, 78% of lower-middle-income countries and 54% of low-income countries have introduced HPV vaccines into their national immunisation programmes.
India's stake is disproportionate. The country reports on the order of 1.25 lakh new cervical cancer cases and close to 80,000 deaths a year, roughly a fifth of the global burden, and about one in four of the women who die of the disease worldwide each year is Indian. Cervical cancer is among the two most common cancers in Indian women.
The WHO's global elimination strategy is the 90-70-90 target for 2030: 90% of girls fully vaccinated against HPV by age 15, 70% of women screened with a high-performance test by 35 and again by 45, and 90% of women with disease receiving treatment. India's campaign attacks the first pillar. The second and third remain the harder ones — screening coverage among Indian women has historically been very low, and vaccination does not substitute for it. A vaccine covering types 16 and 18 leaves roughly 30% of cervical cancers, caused by other oncogenic types, untouched. Those cancers are caught by screening or not at all.
Delivery runs through the existing machinery of the Universal Immunisation Programme, one of the largest public-health programmes in the world, which has carried India's routine childhood immunisation since 1985 and was intensified through Mission Indradhanush from 2014. Adding an adolescent-girl cohort to a system built around infants is itself a structural extension worth noting. For the pathogen side of the story, the viral and bacterial disease notes are the right companion reading.
🔑 Revision block
The milestone. More than 80 lakh HPV vaccine doses administered, announced 11 September 2026 by the Ministry of Health and Family Welfare.
The campaign. National HPV Vaccination Campaign, launched by the Prime Minister in February 2026 — free, voluntary, single-dose, 14-year-old girls, parental consent, government health facilities.
The cohort. About 1.2 crore girls a year, per Registrar General of India 2021 estimates.
Coverage. 100% — Gujarat, Uttar Pradesh, Madhya Pradesh, Mizoram. Above 90% — Bihar, Andhra Pradesh, Assam. Above 85% — Karnataka. Above 60% — Chhattisgarh, Sikkim, Kerala, Telangana, Odisha. Highest absolute number: Uttar Pradesh, over 22 lakh girls.
Platform. U-WIN, for district-level monitoring and identification of missed beneficiaries.
The science. HPV types 16 and 18 cause about 70% of cervical cancers; types 6 and 11 cause most genital warts. Virus-like particle vaccines; prophylactic, not therapeutic. CERVAVAC, Serum Institute of India, quadrivalent (6, 11, 16, 18), authorised 2022.
Safety. Sessions under trained Medical Officers; facilities linked to 24×7 AEFI management; over 800 million doses distributed globally.
Global adoption. 87% of upper-middle-income, 78% of lower-middle-income and 54% of low-income countries have HPV vaccines in their national programmes.
India's burden. Roughly 1.25 lakh new cases and about 80,000 deaths a year — about a fifth of the global burden.
The target. WHO 90-70-90 by 2030: vaccinate, screen, treat.
🎯 Practice MCQs
Q1. The National HPV Vaccination Campaign was launched in: (a) August 2025 (b) February 2026 (c) April 2026 (d) June 2026 → (b).
Q2. The campaign provides HPV vaccination to: (a) All women aged 15 to 45 (b) Girls aged 9 to 14 in three doses (c) 14-year-old girls, single dose, free and voluntary (d) Both boys and girls aged 12 → (c).
Q3. Which HPV types cause roughly 70% of cervical cancers? (a) 6 and 11 (b) 16 and 18 (c) 31 and 33 (d) 45 and 52 → (b).
Q4. Which of these States had not reported 100% coverage of its identified target cohort? (a) Gujarat (b) Madhya Pradesh (c) Mizoram (d) Karnataka → (d) — Karnataka was above 85%.
Q5. The digital platform used to monitor coverage under the campaign is: (a) CoWIN (b) U-WIN (c) e-Sanjeevani (d) ABDM → (b).
Q6. India's first indigenously developed HPV vaccine is: (a) Covovax (b) CERVAVAC (c) Gardasil (d) Cervarix → (b) — Serum Institute of India, quadrivalent.
Q7. The annual cohort of 14-year-old girls in India is estimated at approximately: (a) 60 lakh (b) 80 lakh (c) 1.2 crore (d) 2 crore → (c).
Q8. WHO's global cervical cancer elimination strategy is described by the numbers: (a) 95-95-95 (b) 90-70-90 (c) 70-90-70 (d) 80-80-80 → (b) — vaccinate 90%, screen 70%, treat 90%, by 2030.
Q9. The State with the highest absolute number of girls vaccinated under the campaign is: (a) Madhya Pradesh (b) Bihar (c) Uttar Pradesh (d) Maharashtra → (c) — more than 22 lakh.
Q10. AEFI, in the context of an immunisation programme, stands for: (a) Annual Estimate of Female Immunisation (b) Adverse Events Following Immunization (c) Assured Emergency Facility for Immunisation (d) Advanced Evaluation of Field Immunisation → (b).
Q11. The Universal Immunisation Programme was launched in: (a) 1978 (b) 1985 (c) 1992 (d) 2005 → (b).
Q12. Consider the following: 1. HPV vaccination removes the need for cervical cancer screening in vaccinated women. 2. The HPV vaccine is prophylactic and does not treat an existing infection. (a) 1 only (b) 2 only (c) Both (d) Neither → (b) — vaccines covering types 16 and 18 leave about 30% of cervical cancers untouched, so screening remains essential.
📋 How this gets asked (PYQ pattern)
Public-health items in CDS and OTA papers take four recognisable forms. The pathogen item asks which organism or virus causes a named disease, or which types are oncogenic — HPV, hepatitis B and the vector-borne diseases rotate here. The programme item asks the launch year, the target group and the administering ministry of a scheme, with the Universal Immunisation Programme's 1985 start and Mission Indradhanush's 2014 launch as recurring answers. The platform item tests the digital layer — CoWIN against U-WIN against the Ayushman Bharat Digital Mission — and the trap is treating the COVID platform and the routine-immunisation platform as the same thing. The global-target item asks for the elimination numbers, where 90-70-90 for cervical cancer is routinely confused with the 95-95-95 target used for HIV.
The fresh 2026 hook is the 80 lakh doses, the single-dose schedule for 14-year-olds, and the four States at 100% coverage, most likely as a statement pair combining the target group with the monitoring platform. We describe the recurring pattern here, not any exact past question.
Preparing for CDS or OTA? Health and biology questions carry steady weight in the GK paper, and the ones built on live national campaigns are the easiest to lock in. Build the base with our CDS/OTA general science hub, follow the daily CDS/OTA current affairs, and prepare with our faculty in the upcoming Cavalier courses in Delhi.
✍️ Written by Hitendra Deswal — Economy & current affairs faculty at The Cavalier. Reviewed by the Cavalier Faculty Desk. The Cavalier, founded by ex-Army officers, has trained NDA/CDS/SSB aspirants since 2001 (Facebook · YouTube).
Source: PIB / Ministry of Health and Family Welfare, 11 September 2026. Virology, vaccine composition, disease burden and the WHO elimination targets cross-verified with WHO material and independent medical sources.